Physician profile
Yong Chen
NPI 1477712644
$1,467.09
in general payments reported to CMS, 2019-2025
18 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $624 · 2020: $197 · 2021: $36.21 · 2022: $58.69 · 2023: $53.10 · 2024: $237 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $551.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $234.04 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.38 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $134.85 | 2019-2025 | Wegovy |
| Teva Pharmaceuticals USA, INC. | $121.94 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $103.04 | 2019-2025 | Breztri, Airsupra |
| Merck Sharp & Dohme LLC | $94.62 | 2019-2020 | |
| Amgen INC. | $91.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $90.12 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $88.54 | 2019-2024 | Xarelto |
| Pfizer INC. | $82.80 | 2019-2021 | |
| Astellas Pharma US INC | $67.93 | 2024-2025 | Veozah |
| Amarin Pharma, INC. | $48.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.07 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $37.78 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.94 | 2020-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $21.56 | 2025 | Eliquis |
| Seqirus USA INC | $15.20 | 2019 | |
| Abbott Laboratories | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yong Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.